The Relative Strength ( RS ) Rating for Bio Rad Labs ( BIO ) entered a new percentile Wednesday, with a rise from 77 to 81.
[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the best-performing stocks tend to have an RS Rating north of 80 as they begin their biggest runs.
See How IBD Helps You Make More Money In Stocks
Bio Rad Labs is trying to complete a flat base with a 273.97 entry . See if the stock can break out in volume at least 40% higher than normal. It's a later-stage pattern, and investors should be aware that those involve more risk.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from -72% to 47%. Revenue rose from -2% to 5%.
The company holds the No. 18 rank among its peers in the Medical-Research Equipment/Services industry group. PRA Health Sciences ( PRAH ), Illumina ( ILMN ) and Catalent ( CTLT ) are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
